Dabrafenib (GSK2118436)

目录号:S2807

Dabrafenib (GSK2118436) Chemical Structure

Molecular Weight(MW): 519.56

Dabrafenib (GSK2118436)是一种突变型BRAFV600特异性抑制剂,无细胞试验中IC50为0.7 nM,作用于B-Raf(wt)和c-Raf效果分别低7和9倍。

规格 价格 库存 购买数量  
RMB 1481.39 现货
RMB 733.64 现货
RMB 1056.75 现货
RMB 1394.46 现货
RMB 2235.84 现货
RMB 3261.37 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的6个实验数据:

  • BRAFi/MEKi-resistant A375DR and the parental A375 cells were treated with 2 μM vorinostat and/or the combination of 0.125 μM dabrafenib and 5 nM trametinib. Protein lysates were harvested after 72 hr. Western blot analysis was carried out for p-MEK and p-P90RSK as indicators of activation of MAPK pathway, ac-H3 as indicator for levels of acetylated histone H3 and a-tubulin as a loading control.

    Cell, 2018, 173(6):1413-1425. Dabrafenib (GSK2118436) purchased from Selleck.

    A375P cells were treated with vehicle, the BRAF inhibitor GSK2118436, the MEK inhibitor GSK1120212, 10 uM HCQ, or the indicated combinations. Shown are 48-hour immunoblots directed against the indicated proteins.

    J Clin Invest 2014 24(3), 1406-17. Dabrafenib (GSK2118436) purchased from Selleck.

  • Levels of pERK and tERK in the CLL cells derived from PBMC were measured by Western blot. We used vemurafenib, dabrafenib, and trametinib (0.07 uM) as indicated. One of 3 independent experiments with similar results is shown. CLL cells exposed to dabrafenib or vemurafenib had an elevated pERK/tERK ratio as compared with vehicle (P < 0.01).

    J Clin Invest 2014 124(11), 5074-84. Dabrafenib (GSK2118436) purchased from Selleck.

    Dabrafenib alleviates acetaminophen-induced hepatotoxicity in mice. Mice were treated with 300 mg/kg acetaminophen (i.p.), with or without pretreatment with 300 mg/kg or 100 mg/kg dabrafenib (p.o.).TUNEL staining for nuclear DNA fragmentation in mouse liver cells.

    Cell Death Dis 2014 5, e1278. Dabrafenib (GSK2118436) purchased from Selleck.

  • The effects of inhibitors of mutant BRAFV600 inhibitor dabrafenib on cancer cell growth were evaluated by the MTT assay. Cell growth inhibition of FRO and SW1736 cell lines induced by dabrafenib.

    Transl Res 2014 10.1016/j.trsl.2014.06.005. Dabrafenib (GSK2118436) purchased from Selleck.

    Western blot analysis of p-Erk and total ERK in A375 melanoma cell line after treatment with different doses of Dabrafenib for 48 hours (A). p-ERK signal was normalized with total ERK signal (B), SD and means of the normalized p-ERK values were reported.

    PLoS One, 2016, 11(3):e0152104. Dabrafenib (GSK2118436) purchased from Selleck.

产品安全说明书

Raf抑制剂选择性比较

生物活性

产品描述 Dabrafenib (GSK2118436)是一种突变型BRAFV600特异性抑制剂,无细胞试验中IC50为0.7 nM,作用于B-Raf(wt)和c-Raf效果分别低7和9倍。
靶点
B-Raf (V600E) [3]
(Cell-free assay)
B-Raf [3]
(Cell-free assay)
C-Raf [3]
(Cell-free assay)
0.7 nM 5.2 nM 6.3 nM
体外研究

Dabrafenib对Raf激酶具有选择性,对B-Raf的活性比其它测试过的91%的激酶高400倍。 Dabrafenib抑制B-RafV600E激酶,导致ERK磷酸化降低和抑制细胞的增值,在特异性编码突变的B-RafV600E的癌细胞中细胞停滞在G1期。

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NF63UpRMcW6jc3WgRZN{[Xl? NIi2RYtKdmirYnn0bY9vKG:oIF6teIVzdWmwYXygTIl{KHSjZ3fl[EBDNVKjZjDWOlAxTSCvdYThcpQh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJIlve2WldDDj[YxteyClbz3lfJBz\XO|aX7nJGNFSzN5IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKGKrb4Tpcplt[XSnZD3NSWsheHKxdHXpckBxcG:|cHjvdplt[XSrb36gZpkhSWyyaHHTZ5Jm\W5iYYPzZZkhf2m2aDDJR|UxKG:oIECuNFAxPyEQvF2= NFPGZ5czPDlyME[3Ny=>
SK-MEL-28 NW\jNFZCU2mwYYPlJGF{e2G7 MV:xJIg> NHvLRWxKdmirYnn0bY9vKG:oIFKtVoFnKFZ4MEDFJI12fGGwdDDpckBpfW2jbjDTT{1OTUxvMkigZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4hTVKNIIDoc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNE4xODRizszN M32xTFI1QTByNkez
HepG2 NXPvNoJ7U2mwYYPlJGF{e2G7 MYjJcohq[mm2aX;uJI9nKEJvUnHmJHY3ODCHIH31eIFvfCCrbjDoeY1idiCKZYDHNkBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCHUlugdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjByNDFOwG0> M{HvNVI1QTByNkez
COLO205 NIHVeGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rYTWlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OT{KwOUBk\WyuIIDyc4xq\mW{YYTpc44hf2m2aDDJR|UxKG:oIECuNFA4KM7:TR?= NHWzOJMzPDlyME[3Ny=>
HepG2 NXzXPVQ5TnWwY4Tpc44hSXO|YYm= M1G1clQ2KG2rbh?= NVe3bG1VTE2VTx?= M3vjbWlvcGmkaYTpc44hd2ZiQXzrOUBqdiCWR1[tZoV1[S2|dHnteYxifGWmIHj1cYFvKEincFeyJINmdGy|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKFOvYXSyJJBpd3OyaH;yfYxifGmxbjD0doVifGWmIH\vdkA1PSCvaX7zJJBzcW:{IITvJHRITi2kZYThJJN1cW23bHH0bY9vKG2nYYP1doVlKGGodHXyJFYxKG2rboOgZpkhd2S7c4PlfUBjdG:2IIPjZY5v\XJiYX7hcJl{cXNid3n0bEBKSzVyIH;mJFMvPyEQvF2= NITOUXUzPDlyME[3Ny=>
HFF NGKyU5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYixNEDPxE1? MYS3NkBp NYPlTZVKTE2VTx?= M3PZV2lvcGmkaYTpc44hd2ZicILvcIln\XKjdHnvckBw\iCqdX3hckBJTkZiY3XscJMhcGG{Yn;ybY5oKHerbHSgeJlx\SCELWLh[kB4cXSqIFnDOVAhd2ZiMzFOwG0> MkO0NlM5PDRyM{i=
SK-MEL-28 NHXpW4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;MXWJmOTBizszN NG\s[444OiCq MYrEUXNQ NWrPTXVCUW6qaXLpeIlwdiCxZjDCMXJi\iCYNkCwSUBufXSjboSt[JJqfmWwIGPLMW1GVC1{ODDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMESzJO69VQ>? MX:yN|g1PDB|OB?=
A375P-F11 NGXRc2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLsTFYyOCEQvF2= NGjVVXY4OiCq MWXEUXNQ MV7Jcohq[mm2aX;uJI9nKEJvUnHmJHY3ODCHIH31eIFvfC2mcnn2[Y4hSTN5NWCtSlEyKGOnbHygdJJwdGmoZYLheIlwdiC5aYToJGlEPTBib3[gNE4xPzFizszN NVToN3EyOjN6NESwN|g>
MALME-3M M{nnb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3j4XlExKM7:TR?= M3PXOVczKGh? M3:xT2ROW09? MVzJR|UxRTFibl2= M1XhOVI{QDR2MEO4
UACC-62 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;ZR3cyOCEQvF2= M1G3W|czKGh? MnO1SG1UVw>? M3[xcGlEPTB;MTDuUS=> M1njclI{QDR2MEO4
C32TG MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHLVIkyOCEQvF2= MXq3NkBp M2DlZWROW09? MWHJR|UxRTFibl2= NEjuXVQzOzh2NECzPC=>
SK-MEL-1 NYXWNHBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPQNVAh|ryP MlXaO|IhcA>? M{HFUGROW09? M2r2T2lEPTB;MjDuUS=> MViyN|g1PDB|OB?=
M14 NFLYfmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPYclBmOTBizszN NYDD[Y5ZPzJiaB?= NXLrbXQzTE2VTx?= MoGxTWM2OD1{IH7N Mn\aNlM5PDRyM{i=
SK-MEL-28 MmHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3ibIc5OTBizszN MmPnO|IhcA>? M17kZmROW09? M1;tSGlEPTB;MzDuUS=> NHzMWFkzOzh2NECzPC=>
A375 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fBdVExKM7:TR?= NGLFR3U4OiCq MWDEUXNQ MlP5TWM2OD12IH7N NELueogzOzh2NECzPC=>
DU-4475 M{HKfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoqzNVAh|ryP M{foOlczKGh? MUPEUXNQ MoLxTWM2OD13IH7N NV3uNlZDOjN6NESwN|g>
UACC-257 M1;UcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3WblB4OTBizszN Mn7rO|IhcA>? NUPHS|BMTE2VTx?= MojSTWM2OD14IH7N NWTU[XplOjN6NESwN|g>
Colo 205 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlW5NVAh|ryP NEPKe|Y4OiCq MWXEUXNQ NX:zN2I5UUN3ME23JI5O MnrzNlM5PDRyM{i=
SK-MEL-3 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnWNVAh|ryP MVe3NkBp M4fzd2ROW09? MmnSTWM2OD15IH7N MkfXNlM5PDRyM{i=
SH-4 MoPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jFZlExKM7:TR?= MVS3NkBp M3nmTWROW09? MofoTWM2OD16IH7N MUmyN|g1PDB|OB?=
A101D MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXqxNEDPxE1? M4nPZVczKGh? MVzEUXNQ M3TZN2lEPTB;OTDuUS=> NYW2TWlYOjN6NESwN|g>
ES-2 M{jXUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mni0NVAh|ryP M3nq[VczKGh? M1;VbWROW09? MX3JR|UxRTV|IH7N NVXRVHg6OjN6NESwN|g>
HT-29 NXHaVlE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\kZWtqOTBizszN NGfUeFY4OiCq MV;EUXNQ MXnJR|UxRTZ4IH7N MmrmNlM5PDRyM{i=
SW1417 M2HoW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;Vdmo3OTBizszN Ml;vO|IhcA>? NETMd4JFVVOR M2nCeWlEPTB;MUW4JI5O NV33fm0xOjN6NESwN|g>
SW872 NVvnN5V1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37UelExKM7:TR?= MlPNO|IhcA>? NVjrZVA5TE2VTx?= NXG5PIdoUUN3ME2zO|chdk1? NE\2cXQzOzh2NECzPC=>
RKO NFmwTIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX[xNEDPxE1? MnfVO|IhcA>? NHG4NoZFVVOR MVnJR|UxRTJwNUKyJO69VQ>? MWCyN|g1PDB|OB?=
A673 M{TwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DlXlExKM7:TR?= NFq1[5o4OiCq NFnNN45FVVOR NHvDOFhKSzVyPUGwJO69VQ>? NYPDXlQ2OjN6NESwN|g>
GCT NWD5Nm9RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXqxNEDPxE1? NEL1dlU4OiCq NI[1PVRFVVOR NID0[XdKSzVyPUGwJO69VQ>? NXHVPW5QOjN6NESwN|g>
WM-115 MoHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fYfFExKM7:TR?= MnLJO|IhcA>? NWDr[4M3TE2VTx?= NUTBNY03UUN3ME21JI5O NWX4Noc4OjN6NESwN|g>
YUMAC NYnacXF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDONVAh|ryP NETmeGo4OiCq Mm\6SG1UVw>? NIjnTXFKSzVyPUWgcm0> MnPoNlM5PDRyM{i=
OV-90 M4WxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPUU3RpOTBizszN MmHiO|IhcA>? MoLwSG1UVw>? Mle1TWM2OD1{OTDuUS=> MkTjNlM5PDRyM{i=
NCI-H508 M3HVS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVqxNEDPxE1? M1TLeFczKGh? M1;Mc2ROW09? NH;SR|RKSzVyPUGwJO69VQ>? NEPEeJEzOzh2NECzPC=>
MDA-MB-231 M3HFd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjPcWEyOCEQvF2= MnvmO|IhcA>? MkO3SG1UVw>? NYjXeXBPUUN3ME2xNEDPxE1? MUCyN|g1PDB|OB?=
SW756 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrvNosyOCEQvF2= NYLqSnR3PzJiaB?= MlixSG1UVw>? MUPJR|UxRTFyIN88US=> MnTzNlM5PDRyM{i=
SW-837 MoT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3KSFlqOTBizszN M{T1ZlczKGh? NGPTT|JFVVOR M4nsPWlEPTB;MUCg{txO M3v3VFI{QDR2MEO4
UMUC-3 MmTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEH4[lcyOCEQvF2= M3;hXVczKGh? Ml\jSG1UVw>? MUXJR|UxRTFyIN88US=> MU[yN|g1PDB|OB?=
LS-174T MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHNe2cyOCEQvF2= M{\PSlczKGh? NHnGdYxFVVOR MnnkTWM2OD1zMDFOwG0> NH[5N4ozOzh2NECzPC=>
A549 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4CzRVExKM7:TR?= Mo[yO|IhcA>? MoXHSG1UVw>? MUPJR|UxRTFyIN88US=> MXOyN|g1PDB|OB?=
SHP-77 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M16zfFExKM7:TR?= MmfKO|IhcA>? M{jpdmROW09? M3TOTGlEPTB;MUCg{txO M4HKRlI{QDR2MEO4
SW480 NV;QdXFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;VS|ExKM7:TR?= MljjO|IhcA>? NYnxcoZ1TE2VTx?= MUTJR|UxRTFyIN88US=> M4[4clI{QDR2MEO4
DLD-1 NGfTd5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYCxNEDPxE1? MXu3NkBp NGn2dVFFVVOR MV7JR|UxRTFyIN88US=> MVSyN|g1PDB|OB?=
HCT-116 NEXVS|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4X3flExKM7:TR?= M1fzW|czKGh? NHfWTpZFVVOR NEHpVpZKSzVyPUGwJO69VQ>? MVqyN|g1PDB|OB?=
NCI-H747 MnqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULz[|QyOTBizszN MnzTO|IhcA>? NI\PVJlFVVOR NXXXOZJiUUN3ME2xNEDPxE1? MmjWNlM5PDRyM{i=
T-84 NIq0PYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLteoFxOTBizszN NHToTHI4OiCq NGjh[4xFVVOR Mof2TWM2OD1zMDFOwG0> NYHadlJ3OjN6NESwN|g>
NCI-H460 M2DCcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInKWVcyOCEQvF2= Mn7JO|IhcA>? NX;yPXhqTE2VTx?= MXjJR|UxRTFyIN88US=> M4\RNlI{QDR2MEO4
Calu-6 NGXXN2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXOxNEDPxE1? NVrae3F2PzJiaB?= MoPtSG1UVw>? NVjXeYk5UUN3ME2xNEDPxE1? MX2yN|g1PDB|OB?=
HCC-2998 M4TafWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33JTFExKM7:TR?= M3\rUFczKGh? MXXEUXNQ NHLrO3ZKSzVyPUGwJO69VQ>? MlHiNlM5PDRyM{i=
LS1034 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIj4O2YyOCEQvF2= MVG3NkBp MV\EUXNQ MXfJR|UxRTFyIN88US=> NUTR[Vk1OjN6NESwN|g>
CHP-212 MmnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrwNVAh|ryP NUHjSlRrPzJiaB?= NEjjUIlFVVOR M4C5b2lEPTB;MUCg{txO Ml7zNlM5PDRyM{i=
SK-N-AS MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYSxNEDPxE1? NEDSe|I4OiCq MX7EUXNQ Mnn3TWM2OD1zMDFOwG0> Mn7VNlM5PDRyM{i=
BFTC-905 NH\WeWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3I[nQyOCEQvF2= MonOO|IhcA>? MnrnSG1UVw>? MlTxTWM2OD1zMDFOwG0> MmrVNlM5PDRyM{i=
HuT78 NFS4T4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXKxNEDPxE1? MYS3NkBp NYjsb|hKTE2VTx?= NVnrcVVMUUN3ME21NkBvVQ>? M3z0XFI{QDR2MEO4
RPMI-8226 Ml\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LBTlExKM7:TR?= M2fCU|czKGh? NGDPdIJFVVOR NUfBVZMzUUN3ME2yOlMhdk1? M3[2XVI{QDR2MEO4
BC-3 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vtNlExKM7:TR?= MlG1O|IhcA>? M3TzemROW09? MUfJR|UxRTJ5NzDuUS=> NV\KWG1MOjN6NESwN|g>
ACHN MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3y4TVExKM7:TR?= MmeyO|IhcA>? MYjEUXNQ M{\zXGlEPTB;Mkm0JI5O M365NlI{QDR2MEO4
JRT3-T35 Mn3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnEZWQyOCEQvF2= MojIO|IhcA>? M2O2dGROW09? NWPwN4JRUUN3ME2yPVUhdk1? NH7QdXAzOzh2NECzPC=>
SK-MES-1 NWTTemluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;3SFExKM7:TR?= NITxd5Y4OiCq NFn0U4RFVVOR M1\SdGlEPTB;M{K5JI5O NFnlcXQzOzh2NECzPC=>
CESS M3PHS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWWwPYVMOTBizszN MkLsO|IhcA>? NGfncVVFVVOR M{KwOWlEPTB;NEm3JI5O MYCyN|g1PDB|OB?=
H4 NV3EXW9bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnK[VkyOCEQvF2= NYfy[oF2PzJiaB?= NYLwcpRnTE2VTx?= MXHJR|UxRTZzOTDuUS=> NYPPbHI6OjN6NESwN|g>
BC-1 M{H1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWGxNEDPxE1? NELCR3Q4OiCq NX;xXGRZTE2VTx?= Mk\oTWM2OD15MESgcm0> MYSyN|g1PDB|OB?=
DB M4jUOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVmxNEDPxE1? MV63NkBp MVPEUXNQ M4DzdGlEPTB;OEezJI5O M176S|I{QDR2MEO4
RPMI-6666 NX[3eYZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPFNVAh|ryP M17QVFczKGh? MXjEUXNQ NHnxd5ZKSzVyPUmyPEBvVQ>? M4T6XlI{QDR2MEO4
MC/CAR NXi3S2MyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rKWlExKM7:TR?= MXe3NkBp MkTCSG1UVw>? NF[w[ZNKSzVyPUGuNFAzKM7:TR?= NYXtOHpsOjN6NESwN|g>
SNU-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3PTIoyOCEQvF2= M1zj[|czKGh? MkfpSG1UVw>? NGHZN4JKSzVyPUGuOVAyKM7:TR?= MVuyN|g1PDB|OB?=
CEM/C1 NYfU[mxCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVOxNEDPxE1? M1ro[VczKGh? MVnEUXNQ NF7xUIxKSzVyPUGuO|c{KM7:TR?= MWeyN|g1PDB|OB?=
GDM-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTNdnBbOTBizszN NInTc4E4OiCq Ml24SG1UVw>? M3nVUGlEPTB;MT65PVch|ryP NHO0SnQzOzh2NECzPC=>
HT-1080 MkHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrIOY4yOCEQvF2= MUK3NkBp M1rRWWROW09? M4LXSGlEPTB;Mj6wNFQh|ryP NGLudo0zOzh2NECzPC=>
HL-60 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4e4NlExKM7:TR?= M1vnTVczKGh? M1;6bWROW09? MlTZTWM2OD1{LkG3PEDPxE1? MX6yN|g1PDB|OB?=
C3A MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jGZVExKM7:TR?= M{HwbFczKGh? M2\xO2ROW09? NVfVXop{UUN3ME21MlQyPCEQvF2= NGLmS|AzOzh2NECzPC=>
MES-SA M4nBemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnC[ZVMOTBizszN M{DHdVczKGh? NWDsTWVVTE2VTx?= M4i2OmlEPTB;Nj65PFkh|ryP MX6yN|g1PDB|OB?=
22Rv1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoK1NVAh|ryP MYS3NkBp MX\EUXNQ Mmr2TWM2OD1zMDFOwG0> NGPSWZkzOzh2NECzPC=>
647-V Ml;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1OwNlExKM7:TR?= MkP3O|IhcA>? M3PHXmROW09? NXvJTW1zUUN3ME2xNEDPxE1? NWjmd2lZOjN6NESwN|g>
786-O MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;hNVAh|ryP NVLo[oYyPzJiaB?= NXnjXWJNTE2VTx?= M{nJeWlEPTB;MUCg{txO MkTQNlM5PDRyM{i=
A172 M3yxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVK0[XY1OTBizszN Mof4O|IhcA>? M376TmROW09? MVHJR|UxRTFyIN88US=> MoXoNlM5PDRyM{i=
A204 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHN[pYyOCEQvF2= NUm5WWZHPzJiaB?= M4nNT2ROW09? MoX5TWM2OD1zMDFOwG0> MlvUNlM5PDRyM{i=
A427 NFjzTFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jBPVExKM7:TR?= NHTMbFE4OiCq MnfYSG1UVw>? NEf0fXpKSzVyPUGwJO69VQ>? MUmyN|g1PDB|OB?=
A431 NX7aW4J[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nmVFExKM7:TR?= MlT1O|IhcA>? Moi1SG1UVw>? MoD4TWM2OD1zMDFOwG0> MmfkNlM5PDRyM{i=
A2780 NIXVcJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrDTmIyOCEQvF2= NIPnUI04OiCq MlTqSG1UVw>? NInpWHlKSzVyPUGwJO69VQ>? MnjXNlM5PDRyM{i=
ARH-77 M2nETmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXS[VAyOCEQvF2= M4fwdVczKGh? NYqwSYlMTE2VTx?= NWfWblM1UUN3ME2xNEDPxE1? MojMNlM5PDRyM{i=
Be(2)C NV7TZ4E4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHPNVAh|ryP NF7YfIc4OiCq MXfEUXNQ MmfETWM2OD1zMDFOwG0> NVXzXlJxOjN6NESwN|g>
BT-20 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWWxNEDPxE1? MXy3NkBp NXrGbWI6TE2VTx?= NXfOUW9kUUN3ME2xNEDPxE1? M3\HflI{QDR2MEO4
BxPc3 Mki2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPqPJIyOCEQvF2= MkjkO|IhcA>? NH3jdllFVVOR MUPJR|UxRTFyIN88US=> NITFNoMzOzh2NECzPC=>
C-4 I NFjYOoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vPVVExKM7:TR?= Mk\ZO|IhcA>? MmiySG1UVw>? MXHJR|UxRTFyIN88US=> M3PQWVI{QDR2MEO4
C33A NWHJPGhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TVWFExKM7:TR?= Mmi2O|IhcA>? M3zsfGROW09? MkHwTWM2OD1zMDFOwG0> NUKzNJFHOjN6NESwN|g>
CAL-27 M2P0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjpNVAh|ryP MVy3NkBp NWnWcJpXTE2VTx?= NYT4RWp6UUN3ME2xNEDPxE1? NH3TTVEzOzh2NECzPC=>
CAL-62 M3LiUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7Ucod4OTBizszN M4m3VlczKGh? M1fzbmROW09? Mn7UTWM2OD1zMDFOwG0> MnrJNlM5PDRyM{i=
Calu-3 MlXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\i[GsyOCEQvF2= MlLHO|IhcA>? NXzZbGpYTE2VTx?= MoTqTWM2OD1zMDFOwG0> MmXwNlM5PDRyM{i=
CaOV3 NWPpWYQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPSe3J2OTBizszN MWC3NkBp MlTGSG1UVw>? NULvR3FMUUN3ME2xNEDPxE1? Moj4NlM5PDRyM{i=
CGTHW1 M4H1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX:xNEDPxE1? NI[0R5Y4OiCq NFjJPGVFVVOR MXLJR|UxRTFyIN88US=> MXWyN|g1PDB|OB?=
CHL-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUWxNEDPxE1? NUe5W29UPzJiaB?= NF7EWmZFVVOR NF7CWHBKSzVyPUGwJO69VQ>? M1q3VFI{QDR2MEO4
Colo320DM NV20e4R[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfTc5VqOTBizszN M1zKWVczKGh? M{iwW2ROW09? NW\MRlg5UUN3ME2xNEDPxE1? NIDWRpEzOzh2NECzPC=>
Colo704 M4Pw[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nYclExKM7:TR?= MXS3NkBp NVS4[ZpWTE2VTx?= NHnkUXFKSzVyPUGwJO69VQ>? NF7Rd|EzOzh2NECzPC=>
COR-L23 M2KxU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rRb|ExKM7:TR?= NGC4cFY4OiCq M3[zTWROW09? MXTJR|UxRTFyIN88US=> M{\3VFI{QDR2MEO4
CRO-AP2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2m1XFExKM7:TR?= NHvwPY04OiCq M2OyOmROW09? MnvTTWM2OD1zMDFOwG0> MlXTNlM5PDRyM{i=
Daudi MlXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV2xNEDPxE1? M2i3NVczKGh? NFHKbWtFVVOR NITaV2hKSzVyPUGwJO69VQ>? MWSyN|g1PDB|OB?=
DOTC 24510 NWrmVo5wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfkVZIyOCEQvF2= MUG3NkBp M4izTmROW09? MV7JR|UxRTFyIN88US=> NEnDTIYzOzh2NECzPC=>
DU-145 NGXySmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLBNVAh|ryP MmHFO|IhcA>? MU\EUXNQ MUDJR|UxRTFyIN88US=> Ml3zNlM5PDRyM{i=
EB-3 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXuWXMyOCEQvF2= NGi5doI4OiCq MnPoSG1UVw>? MlTiTWM2OD1zMDFOwG0> M1KzVlI{QDR2MEO4
EFM-19 MkLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\XWI0yOCEQvF2= Mn3tO|IhcA>? MYLEUXNQ NF;HTGtKSzVyPUGwJO69VQ>? M4fO[|I{QDR2MEO4
EKVX M4fiSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWSxNEDPxE1? NFTtSmw4OiCq NVzNdHhGTE2VTx?= MkXZTWM2OD1zMDFOwG0> MUGyN|g1PDB|OB?=
FaDu NVXXNmllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfSXZMyOCEQvF2= M4nMdFczKGh? MXrEUXNQ MUPJR|UxRTFyIN88US=> NVy0OIJSOjN6NESwN|g>
G401 NInNc4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWOxNEDPxE1? MVi3NkBp NX3sclE4TE2VTx?= MmjWTWM2OD1zMDFOwG0> MmDuNlM5PDRyM{i=
HCC-70 NX;GUYIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXBSpFGOTBizszN M4C4[lczKGh? NV\hb5FQTE2VTx?= M3PwZmlEPTB;MUCg{txO NXvxWIFMOjN6NESwN|g>
HCC-1954 NYn0cpFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;3NVAh|ryP MWi3NkBp MWDEUXNQ M{HyW2lEPTB;MUCg{txO MYSyN|g1PDB|OB?=
Hela NFjT[ZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPUNVAh|ryP MVq3NkBp NIqxfW5FVVOR MoXtTWM2OD1zMDFOwG0> NHfzdG8zOzh2NECzPC=>
Hep3B NITZeWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7UXHUyOCEQvF2= NFLHfWM4OiCq NUPUcm9lTE2VTx?= NUO1UVR5UUN3ME2xNEDPxE1? NUj0foFPOjN6NESwN|g>
HMCB M3;JO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUWxNEDPxE1? NIrHd|E4OiCq M13R[2ROW09? NFvOepNKSzVyPUGwJO69VQ>? M1K4UFI{QDR2MEO4
HN5 NYj4cZpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVWxNEDPxE1? MkHTO|IhcA>? MWXEUXNQ NX:yXmtxUUN3ME2xNEDPxE1? NYTwbnVIOjN6NESwN|g>
HOS NHLiNYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoD2NVAh|ryP NWjhbZRIPzJiaB?= M2LNe2ROW09? MknuTWM2OD1zMDFOwG0> MYqyN|g1PDB|OB?=
HPAF-II M3vRPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLwNVAh|ryP NWKwWGxNPzJiaB?= NWG3PJVvTE2VTx?= M3zlZmlEPTB;MUCg{txO NFvQVZEzOzh2NECzPC=>
Hs746.T MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvNNVAh|ryP NX;PRnlmPzJiaB?= MmOzSG1UVw>? MV\JR|UxRTFyIN88US=> NGC3WVIzOzh2NECzPC=>
HT M2rJRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXPNVAh|ryP NH31eFk4OiCq NIHPZmVFVVOR MoD2TWM2OD1zMDFOwG0> MUOyN|g1PDB|OB?=
HT-3 NFXGV|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVOxNEDPxE1? MXW3NkBp MVzEUXNQ MYHJR|UxRTFyIN88US=> NH\yTFAzOzh2NECzPC=>
HuNS-1 M1;hVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGm3VZAyOCEQvF2= NXHFVWtzPzJiaB?= MV\EUXNQ MVPJR|UxRTFyIN88US=> NUXqRYxmOjN6NESwN|g>
IGROV1 NYLyT491T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\p[I0zOTBizszN NX\UOnFCPzJiaB?= MULEUXNQ MXXJR|UxRTFyIN88US=> NHTEW4szOzh2NECzPC=>
J82 NHzLXXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjJRlgyOCEQvF2= M4GwcVczKGh? MnjQSG1UVw>? NE\QV2ZKSzVyPUGwJO69VQ>? MkP0NlM5PDRyM{i=
JM1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX2xNEDPxE1? NH;Rcm04OiCq MYrEUXNQ MVLJR|UxRTFyIN88US=> NUO2c5dnOjN6NESwN|g>
Kato III NF;rfIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXFNHBROTBizszN NUTje3N4PzJiaB?= NXfwVIduTE2VTx?= NEnxTYtKSzVyPUGwJO69VQ>? NH\mT3kzOzh2NECzPC=>
KHOS-240S NXjkV5JWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWmxNEDPxE1? M13N[VczKGh? MXXEUXNQ MonvTWM2OD1zMDFOwG0> MmXmNlM5PDRyM{i=
KM-12 MnvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjJNVAh|ryP NFexNHc4OiCq M2nWU2ROW09? MnW0TWM2OD1zMDFOwG0> M1T0dFI{QDR2MEO4
KPL-1 MmHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXO4UHBWOTBizszN NE\NdnU4OiCq MU\EUXNQ NYTW[JZbUUN3ME2xNEDPxE1? Mn7aNlM5PDRyM{i=
KYSE-30 NWTzNYxMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1roWVExKM7:TR?= MkTvO|IhcA>? NV7TVFl7TE2VTx?= M2G4bWlEPTB;MUCg{txO NWjqemx1OjN6NESwN|g>
LNCaP NIHzWW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M325SVExKM7:TR?= NYq1[lRmPzJiaB?= NXXLVm9iTE2VTx?= NGP5c45KSzVyPUGwJO69VQ>? NUi5THN6OjN6NESwN|g>
MCF-7 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHRNVAh|ryP NXT2R5ZjPzJiaB?= NXr1XY1MTE2VTx?= NVzxOpRxUUN3ME2xNEDPxE1? NYnGdXhSOjN6NESwN|g>
MC-IXC NILyZY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoK0NVAh|ryP NGjrT5c4OiCq MWnEUXNQ MYjJR|UxRTFyIN88US=> M4rlVFI{QDR2MEO4
MDA-MB-175 VII NHT3bpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\TVVV4OTBizszN NEfHU|g4OiCq MkLjSG1UVw>? M1TlPWlEPTB;MUCg{txO M3P6clI{QDR2MEO4
MDA-MB-468 NGDJVoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXqxNEDPxE1? NF\0b|Y4OiCq MWPEUXNQ NIrH[IZKSzVyPUGwJO69VQ>? NETxTXIzOzh2NECzPC=>
MiaPaCa MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWH6XIN4OTBizszN NHzWd5c4OiCq NFrTRpVFVVOR MUHJR|UxRTFyIN88US=> NXTGUY5kOjN6NESwN|g>
Molt-4 NWHsdYVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;tUlExKM7:TR?= Ml;tO|IhcA>? M{DJZ2ROW09? NEDmVmtKSzVyPUGwJO69VQ>? MlWwNlM5PDRyM{i=
NCI-ADR/RES NEPYbFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jlT|ExKM7:TR?= MXi3NkBp MWrEUXNQ MnnlTWM2OD1zMDFOwG0> NGnaUHQzOzh2NECzPC=>
NCI-H69 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGj6O3kyOCEQvF2= NFPRT|Q4OiCq M3vDW2ROW09? M3X0eWlEPTB;MUCg{txO M4P0TlI{QDR2MEO4
NCI-H82 MlH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY[xNEDPxE1? M4DUNVczKGh? NET0dYdFVVOR NFrHSGFKSzVyPUGwJO69VQ>? MmTINlM5PDRyM{i=
NCI-N87 M4TC[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUOxNEDPxE1? NW\IXoE1PzJiaB?= M1LkeWROW09? MojNTWM2OD1zMDFOwG0> M{nRZ|I{QDR2MEO4
NCI-H146 NHPaNm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVmxNEDPxE1? MmTQO|IhcA>? MXrEUXNQ Mk\WTWM2OD1zMDFOwG0> MVSyN|g1PDB|OB?=
NCI-H157 M4PIfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIL1OHgyOCEQvF2= NUDsOXUyPzJiaB?= NXHmNmxJTE2VTx?= M2\qfGlEPTB;MUCg{txO M{PvblI{QDR2MEO4
NCI-H187 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7TNVAh|ryP NU\jPIdrPzJiaB?= MXjEUXNQ MmrUTWM2OD1zMDFOwG0> MkDjNlM5PDRyM{i=
NCI-H209 MmniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHkWZM{OTBizszN NH60OGU4OiCq MmXpSG1UVw>? NXrBRmIxUUN3ME2xNEDPxE1? MYOyN|g1PDB|OB?=
NCI-H226 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXudlEyOCEQvF2= NEfTO2g4OiCq NF3YU49FVVOR MmnrTWM2OD1zMDFOwG0> M3fEWFI{QDR2MEO4
NCI-H292 M3XNXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXexNEDPxE1? NG\SOWY4OiCq MkXMSG1UVw>? NWHzcXA5UUN3ME2xNEDPxE1? M3r0VVI{QDR2MEO4
NCI-H322 M1LvTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHnNVAh|ryP M4ru[FczKGh? MXLEUXNQ M1L5Z2lEPTB;MUCg{txO MmnqNlM5PDRyM{i=
NCI-H358 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPiUHUyOCEQvF2= MnTpO|IhcA>? NGnZUGZFVVOR MnG0TWM2OD1zMDFOwG0> NHTFd3AzOzh2NECzPC=>
NCI-H520 NYfFSIxtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVGxNEDPxE1? M1TXWlczKGh? MVjEUXNQ NXjvdlRVUUN3ME2xNEDPxE1? M17BZ|I{QDR2MEO4
NCI-H526 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XLbFExKM7:TR?= MYS3NkBp M37RfWROW09? MkPlTWM2OD1zMDFOwG0> MXuyN|g1PDB|OB?=
NCI-H630 NE[yTFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjSO3QyOCEQvF2= M1iyfFczKGh? NH;wNWxFVVOR M4\2WWlEPTB;MUCg{txO MnnkNlM5PDRyM{i=
NCI-H661 Mn;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUCxNEDPxE1? NIPsOnk4OiCq M3rOPWROW09? M17nTGlEPTB;MUCg{txO NEG3enYzOzh2NECzPC=>
NCI-H716 Ml[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXhNVAh|ryP MXG3NkBp MkLYSG1UVw>? MnjJTWM2OD1zMDFOwG0> NYjkUZFROjN6NESwN|g>
NCI-H1563 M1q2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVOxNEDPxE1? MlXnO|IhcA>? MV7EUXNQ M3;nc2lEPTB;MUCg{txO MnnhNlM5PDRyM{i=
NCI-H1792 NELl[JBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjxZ4wyOCEQvF2= MUS3NkBp MVvEUXNQ M{TRcmlEPTB;MUCg{txO MljiNlM5PDRyM{i=
NCI-H2030 M2jjO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1H6dlExKM7:TR?= MlS1O|IhcA>? M4TUOWROW09? MkXITWM2OD1zMDFOwG0> MX[yN|g1PDB|OB?=
NCI-H2052 NGfwOotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jtRlExKM7:TR?= NFzUN5I4OiCq NYTCcIRiTE2VTx?= MnHjTWM2OD1zMDFOwG0> NInhOFIzOzh2NECzPC=>
NCI-H2122 M3XLOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vnXlExKM7:TR?= MnjFO|IhcA>? M3TWV2ROW09? M1zBeWlEPTB;MUCg{txO NFjP[4wzOzh2NECzPC=>
NCI-H2228 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVixNEDPxE1? MVW3NkBp NHHIVIlFVVOR MlX5TWM2OD1zMDFOwG0> NYWwU5NIOjN6NESwN|g>
OE-19 M4nEPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYSxNEDPxE1? NV\kUoF7PzJiaB?= MkTMSG1UVw>? M1f0PGlEPTB;MUCg{txO NIjmeZAzOzh2NECzPC=>
OE-21 NXzXemlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7Bb3YyOCEQvF2= M3zQS|czKGh? NFrZR21FVVOR MmLmTWM2OD1zMDFOwG0> M1yxPVI{QDR2MEO4
OE-33 NWm2UnZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLpNVAh|ryP NIPob2U4OiCq NUfrOIJiTE2VTx?= MkXETWM2OD1zMDFOwG0> NFzpSmgzOzh2NECzPC=>
OVCAR-3 M2Pxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmCxNVAh|ryP NV\IfWFqPzJiaB?= NVzUeHp4TE2VTx?= NXXBWZBjUUN3ME2xNEDPxE1? M3T2d|I{QDR2MEO4
OVCAR-4 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWH3XIpbOTBizszN NWDqU2N2PzJiaB?= Mnv6SG1UVw>? M3zEbGlEPTB;MUCg{txO Mn;rNlM5PDRyM{i=
OVCAR-5 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7iUHF3OTBizszN MonkO|IhcA>? M1\Gc2ROW09? MoHtTWM2OD1zMDFOwG0> MVuyN|g1PDB|OB?=
P3HR-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn33NVAh|ryP MVm3NkBp NEnOepNFVVOR M3K3V2lEPTB;MUCg{txO MVWyN|g1PDB|OB?=
PC-3 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnj4NVAh|ryP NFnpO|c4OiCq NYj0NIxqTE2VTx?= M{H0dmlEPTB;MUCg{txO M2H5WVI{QDR2MEO4
Raji NGXjfINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPmNVAh|ryP Ml25O|IhcA>? MlqzSG1UVw>? NHSyO2tKSzVyPUGwJO69VQ>? M130S|I{QDR2MEO4
RD MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFm0S40yOCEQvF2= M3;nWFczKGh? MVXEUXNQ NXT2RmJkUUN3ME2xNEDPxE1? NFPRWpUzOzh2NECzPC=>
RD-ES MlrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnscocyOCEQvF2= MVi3NkBp MYXEUXNQ NV71[XlOUUN3ME2xNEDPxE1? MojZNlM5PDRyM{i=
RL NXvX[FU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjM[JJ[OTBizszN NV7We5VzPzJiaB?= NGL3U|RFVVOR NVLaNpU6UUN3ME2xNEDPxE1? NXjXTXZzOjN6NESwN|g>
SaOS2 M4TEUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1qzfVExKM7:TR?= MlfuO|IhcA>? MUDEUXNQ MX\JR|UxRTFyIN88US=> MXqyN|g1PDB|OB?=
SCC-9 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTmOnREOTBizszN MoriO|IhcA>? M3zYN2ROW09? NXTxdmVYUUN3ME2xNEDPxE1? M3LseVI{QDR2MEO4
SCC-12 MnyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHZ[|AyOCEQvF2= M2PHOlczKGh? MUHEUXNQ M1u1NmlEPTB;MUCg{txO M3PIOVI{QDR2MEO4
SCC-13 M{nBe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\6XFExKM7:TR?= Ml3IO|IhcA>? MnvHSG1UVw>? NGnJWoJKSzVyPUGwJO69VQ>? NXf2XItbOjN6NESwN|g>
SCC-15 NEjXTWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjBS3IyOCEQvF2= MX[3NkBp Mkj5SG1UVw>? NWe3Z4RwUUN3ME2xNEDPxE1? M{\VNlI{QDR2MEO4
SCC-25 Mon4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2qzVVExKM7:TR?= MWW3NkBp NFfud41FVVOR MV;JR|UxRTFyIN88US=> M2G1flI{QDR2MEO4
SCLC-3 MmLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHrbVgyOCEQvF2= M2T6ZVczKGh? NYG1bXVvTE2VTx?= MXPJR|UxRTFyIN88US=> NF;nOo8zOzh2NECzPC=>
SF-268 NGnCVXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEC2Ro4yOCEQvF2= M3vJXVczKGh? M4q3T2ROW09? MlXoTWM2OD1zMDFOwG0> MV6yN|g1PDB|OB?=
SF-295 MmPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWmxNEDPxE1? MoXoO|IhcA>? NXzocYVpTE2VTx?= NIPNNoFKSzVyPUGwJO69VQ>? NV3YfFhkOjN6NESwN|g>
SJRH30 M3:4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4niSlExKM7:TR?= NVHtSGV5PzJiaB?= M3vl[GROW09? M1vnXmlEPTB;MUCg{txO MVyyN|g1PDB|OB?=
SK-BR-3 MlvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoexNVAh|ryP M2HHWFczKGh? NFTmOVRFVVOR NFWxbYdKSzVyPUGwJO69VQ>? NHfnT44zOzh2NECzPC=>
SK-LMS-1 M2PSOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXMNVAh|ryP Mn;pO|IhcA>? MnLaSG1UVw>? M17veWlEPTB;MUCg{txO NVPsUWhyOjN6NESwN|g>
SK-N-DZ NYfoNXBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUKxNEDPxE1? M3TSOlczKGh? M3m0SWROW09? MVLJR|UxRTFyIN88US=> MUKyN|g1PDB|OB?=
SK-N-F1 MlfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWCwR4tWOTBizszN NWPETWJFPzJiaB?= NIDlfFlFVVOR Mnm0TWM2OD1zMDFOwG0> MkfSNlM5PDRyM{i=
SKOV-3 MlzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3SwOlExKM7:TR?= NV7GVYpxPzJiaB?= MnTiSG1UVw>? M{\ZcGlEPTB;MUCg{txO NUHrS3lsOjN6NESwN|g>
SK-UT-1 NYnnXW5[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3tcZAyOCEQvF2= MYG3NkBp Mo\FSG1UVw>? MX3JR|UxRTFyIN88US=> NUPMSGRZOjN6NESwN|g>
SN12C MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH65c4kyOCEQvF2= NYHlc2pvPzJiaB?= M2PXT2ROW09? M2D6b2lEPTB;MUCg{txO MXiyN|g1PDB|OB?=
SNB-19 NGLFVnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXexNEDPxE1? NYH1WXVFPzJiaB?= MV\EUXNQ M3HVPGlEPTB;MUCg{txO NGeybnMzOzh2NECzPC=>
SNU-5 NVLXWplxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHjeFNPOTBizszN NH25Opc4OiCq NVrTPI9qTE2VTx?= MoHzTWM2OD1zMDFOwG0> NHz2Xm4zOzh2NECzPC=>
SNU-16 MnXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LkRVExKM7:TR?= MYi3NkBp MmizSG1UVw>? M{P5OWlEPTB;MUCg{txO Ml7lNlM5PDRyM{i=
SNU-398 M4LQcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvFNVAh|ryP M3viblczKGh? M{LwS2ROW09? M2jmWGlEPTB;MUCg{txO M4PhOFI{QDR2MEO4
SNU-449 NEPKPGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MortNVAh|ryP NXXidWtPPzJiaB?= NIfOVVJFVVOR MlH2TWM2OD1zMDFOwG0> MViyN|g1PDB|OB?=
SR NHix[4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3DUpYyOCEQvF2= NInVS4Y4OiCq NWPJdmd4TE2VTx?= M4C4PGlEPTB;MUCg{txO M3\XSFI{QDR2MEO4
ST486 MnXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPtc28yOCEQvF2= NF;yT4M4OiCq M{XmRWROW09? MkG1TWM2OD1zMDFOwG0> NGnFRpozOzh2NECzPC=>
SW579 Mk[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVqxNEDPxE1? MUG3NkBp MXrEUXNQ MYHJR|UxRTFyIN88US=> NFmzNJMzOzh2NECzPC=>
SW684 NHrFcppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXrW4EyOCEQvF2= MYK3NkBp M4nHUWROW09? MWTJR|UxRTFyIN88US=> MXWyN|g1PDB|OB?=
SW-780 NUGxUHpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nBXFExKM7:TR?= MYq3NkBp MlPPSG1UVw>? M4jpRmlEPTB;MUCg{txO M{\5eVI{QDR2MEO4
SW900 MkTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnQNVAh|ryP MkTSO|IhcA>? NFzMUmxFVVOR M1qyfGlEPTB;MUCg{txO NXf6bowyOjN6NESwN|g>
SW1088 M{nwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXWyRVN2OTBizszN Mn24O|IhcA>? NWPvOolxTE2VTx?= MnH3TWM2OD1zMDFOwG0> MlWzNlM5PDRyM{i=
SW1463 M3Wzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TBPVExKM7:TR?= MnfCO|IhcA>? MVfEUXNQ NUXSVY1vUUN3ME2xNEDPxE1? NGnKN5YzOzh2NECzPC=>
SW1990 NIrvfpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWWxNEDPxE1? M3vUZVczKGh? MWHEUXNQ M1XQdmlEPTB;MUCg{txO Mkn2NlM5PDRyM{i=
T47D MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHFNVAh|ryP MlnVO|IhcA>? MWrEUXNQ MWrJR|UxRTFyIN88US=> NVPXXmpIOjN6NESwN|g>
TE381.T M4H0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfUNVAh|ryP NV3odJZHPzJiaB?= NUS0SG5UTE2VTx?= MV\JR|UxRTFyIN88US=> NIXkbXYzOzh2NECzPC=>
TK-10 NV;Bd|cyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVKxNEDPxE1? NVy2WWhYPzJiaB?= NFSwcVZFVVOR MnzHTWM2OD1zMDFOwG0> NUWzSGdROjN6NESwN|g>
U2OS Mnv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PhfVExKM7:TR?= MVe3NkBp M1TJNmROW09? M3nl[GlEPTB;MUCg{txO NV[wc5NTOjN6NESwN|g>
U251 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2D1VVExKM7:TR?= M17pVlczKGh? M1\YNmROW09? NIq3SW5KSzVyPUGwJO69VQ>? MkfLNlM5PDRyM{i=
UACC-812 M1z4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX:xdXM2OTBizszN M2jzV|czKGh? NGTkOnFFVVOR Mn3RTWM2OD1zMDFOwG0> MnvFNlM5PDRyM{i=
YAPC MoTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYCxNEDPxE1? M4[zWFczKGh? NWPTb29{TE2VTx?= M2DYPGlEPTB;MUCg{txO M1zrNlI{QDR2MEO4
ZR-75-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUixNEDPxE1? MU[3NkBp NUXyfo57TE2VTx?= NIDVbIxKSzVyPUGwJO69VQ>? MkXGNlM5PDRyM{i=
A375 MoO3SpVv[3Srb36gZZN{[Xl? NXXDWFhoOS5{IN88US=> NWGxR45[PCCq M{DqTGROW09? NIPGNYZKdmirYnn0bY9vKG:oIIDoc5NxcG:{eXzheIlwdiCxZjDNSWstKEWUSzygZY5lKFN4UB?= NEL2ZY4zOjN6OUS3NS=>
YUSIT1 NFq2PXNHfW6ldHnvckBie3OjeR?= NV22SYdbTE2VTx?= Moj5doVlfWOnZDDz[Y5{cXSrdnn0fUB4cXSqIFnDOVAhRiByLkWg{txO NVnwNnZvOjJ|OEm0O|E>
MeWo M{\BV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkHMSG1UVw>? NHO3NphKSzVyIE2gPVg4KG6P MnqyNlYxOTh3MkS=
WiDr NV;pdocxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4DvPGROW09? Mo\HTWM2OCB;IEe2JI5O MkLYNlYxOTh3MkS=
Colo-205 NHroRYZHfW6ldHnvckBie3OjeR?= Mmj2NUDPxE1? M2O5UVQh\A>? MkHGSG1UVw>? MVvJcoR2[2WmIHGgbIlocGy7IHPvcZBiemGkbHWgZ49ueGGldHnvckBxcGWwb4T5dIU> M1vq[lI2OzhzMUWy
RBW-1 MYTGeY5kfGmxbjDhd5NigQ>? MXixJO69VQ>? NUe4fJdHTE2VTx?= NITIS2RPdyC{ZXT1Z5Rqd25ib3[gUYVsKDFxMjDwbI9{eGixconsZZRqd25? NU\WboVGOjR6OEW2PVA>
RBO-1 NXq5TXRnTnWwY4Tpc44h[XO|YYm= NUThe|lrOSEQvF2= MVLEUXNQ NELETYVKdmirYnn0bY9vKG:oIF3lb{AyNzJicHjvd5Bpd3K7bHH0bY9v NVfrZ3lQOjR6OEW2PVA>
RBO-2 M2XSfWZ2dmO2aX;uJIF{e2G7 MmTvNUDPxE1? NYH2Z|N2TE2VTx?= NH;TdYRKdmirYnn0bY9vKG:oIDDN[YshOS9{IIDoc5NxcG:{eXzheIlwdg>? MXWyOFg5PTZ7MB?=
RBOW MVvGeY5kfGmxbjDhd5NigQ>? M3TPXlEh|ryP MV3EUXNQ M1X3UGlvcGmkaYTpc44hd2ZiIF3lb{AyNzJicHjvd5Bpd3K7bHH0bY9v NU\WSmFSOjR6OEW2PVA>
M257 NFrKOmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7ofFcyODBibl2= MYS3NkBp MYPEc4V{KG6xdDDpcohq[mm2IIDyc4xq\mW{YYTpc44hd2ZiTUK1O{Bk\WyuIHjhdoJwfXKrbnege4lt\CC2eYDlJGJTSUZ? MYmyN|MyPzR2Nh?=
LCP MoSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XzdFExOCCwTR?= MUC3NkBp NXHFRZcxUW6qaXLpeIlwdiCxZjDwdo9tcW[ncnH0bY9vKG:oIFzDVEBk\WyuIHjhdoJwfXKrbnegRnJCTiCYNkCwVkBufXSjboTheIlwdg>? MlfrNlM{OTd2NE[=
WM266 NU\UUItYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnNNnYyODBibl2= M3XMXlczKGh? NV;RWGdCUW6qaXLpeIlwdiCxZjDwdo9tcW[ncnH0bY9vKG:oIGfNNlY3KGOnbHygbIFz[m:3cnnu[{BDWkGIIG[2NFFFKG23dHHueIF1cW:w MoO2NlM{OTd2NE[=
M257 NEXQUIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHrNVAxKG6P NWDnemVYPzJiaB?= NEXKUYdFd2W|IH7veEBqdmirYnn0JGVTUzFvMjDwbI9{eGixconsZZRqd25iaX6gUVI2PyClZXzsJIhiemKxdYLpcochf2muZDD0fZBmKEKUQV[= MmOwNlM{OTd2NE[=
LCP Ml;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkm3NVAxKG6P MYO3NkBp MmGwTY5pcWKrdDDFVmsyNTJicHjvd5Bpd3K7bHH0bY9vKGmwIFzDVEBk\WyuIHjhdoJwfXKrbnegRnJCTiCYNkCwVkBufXSjboTheIlwdg>? NULsfI5xOjN|MUe0OFY>
WM266 NUPacm9vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\4NVAxKG6P M4rKXVczKGh? NETLNYtKdmirYnn0JGVTUzFvMjDwbI9{eGixconsZZRqd25iaX6gW20zPjZiY3XscEBp[XKkb4XybY5oKEKUQV[gWlYxOERibYX0ZY51[XSrb36= NYn6eZZiOjN|MUe0OFY>

... Click to View More Cell Line Experimental Data

体内研究 Dabrafenib(口服)抑制B-RafV600E突变的黑色素瘤(A375P)的生长,在免疫受损小鼠中皮下注射结肠癌(Colo205),Dabrafenib(口服)同样能抑制肿瘤生长。 [1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度 (25°C)

体外 DMSO 30 mg/mL (57.74 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
30% PEG400+0.5% Tween80+5% propylene glycol
8 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 519.56
化学式

C23H20F3N5O2S2

CAS号 1195765-45-7
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01153763 Completed Melanoma GlaxoSmithKline August 9 2010 Phase 2
NCT02858921 Recruiting Melanoma Melanoma Institute Australia|Merck Sharp & Dohme Corp.|Novartis November 8 2017 Phase 2
NCT01978236 Terminated Melanoma and Brain Metastases GlaxoSmithKline April 8 2014 Phase 2
NCT01682083 Active not recruiting Melanoma Novartis Pharmaceuticals|Novartis January 8 2013 Phase 3
NCT01340833 Completed Cancer GlaxoSmithKline June 8 2011 Phase 1
NCT01723202 Active not recruiting Follicular Thyroid Cancer|Insular Thyroid Cancer|Papillary Thyroid Cancer|Recurrent Thyroid Cancer Manisha Shah|National Comprehensive Cancer Network|Ohio State University Comprehensive Cancer Center November 7 2012 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

相关Raf产品

Tags: 购买Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436)供应商 | 采购Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436)价格 | Dabrafenib (GSK2118436)生产 | 订购Dabrafenib (GSK2118436) | Dabrafenib (GSK2118436)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID